We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections

By LabMedica International staff writers
Posted on 23 Feb 2024

Annually, a staggering half a million people, including numerous children and young individuals, succumb to serious infections caused by the group A streptococcal (Strep A) bacteria globally. More...

Strep A is highly transmissible and spreads from person to person mostly via the respiratory route from sore throats. Strep A is typically known for causing sore throats and skin infections in younger children.  In rare cases, it can lead to more severe conditions like sepsis and toxic shock if the bacteria invade the bloodstream or tissue. While adults are often immune to Strep A sore throats and skin infections, both adults and children are very susceptible to the invasive form of the infection. A particularly alarming consequence of repeated Strep A infections is the autoimmune-induced damage to heart valves, termed rheumatic heart disease (RHD). RHD affects approximately 50 million people worldwide, predominantly in middle- and low-income countries. Currently, there is no vaccine available for Strep A. The development of immunity to Strep A over time, including the identification of specific bacterial antigens crucial for targeting by the immune system or future vaccines, remains poorly understood. Additionally, the distinction between detrimental immune overreactions to Strep A, leading to RHD, and the desirable protective immunity is not clearly defined.

In response to this global health challenge, an international collaboration of scientists has established a comprehensive network to investigate the bacterial causes of sepsis and heart damage caused by Strep A. The iSpy Network (immunity to Streptococcus pyogenes), led by Imperial College London (London, UK), along with the University of California San Diego (La Jolla, CA, USA), unites 28 researchers from 11 countries. This diverse group of experts in immunology, infectious disease, epidemiology, vaccinology, and experimental medicine will engage in a five-year project. Their goal is to utilize a broad spectrum of advanced techniques to delve into Strep A immunity with unprecedented detail, ultimately contributing significantly to reducing the global impact of Strep A.

The iSpy-LIFE sub-network aims to uncover how effective immunity to Strep A develops in children, following natural infection over time. This research, involving young children, school-age pupils, and adults, may provide insights into genuine immunity against Strep A and guide the development of a vaccine that mimics and accelerates this immunity in children. Additionally, the iSpy-EXPLORE sub-network is set to explore the nature of protective immune responses in experimental models exposed to promising Strep A vaccine candidates. It will also assess human immune responses in healthy volunteers experimentally exposed to Strep A infections. Collectively, these efforts are poised to enhance understanding of both beneficial and detrimental immunity to Strep A, paving the way for a future vaccine that could protect against strep throat, invasive infections, and RHD.

“The RHD patients we see in LMICs generally present with advanced disease and complications such as heart failure,” said Professor Liesl Zuhlke, a pediatric cardiologist at The University of Cape Town and iSpy team member. “Many require cardiac surgery or percutaneous intervention which are often not available, resulting in significant mortality and morbidity and incurring huge out-of-pocket costs to families and communities. We desperately need data on transitions between the various forms of Strep A diseases and how we can intervene to prevent these manifestations.”

Related Links:
Imperial College London
University of California San Diego 


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.